Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder

Minjian Wang,1–4 Li Jiang,2–5 Xiaoju Tang5 1Department of Psychology, 2Ministry of Education Key Laboratory of Child Development and Disorders, 3Key Laboratory of Pediatrics in Chongqing, 4Chongqing International Science and Technology Cooperation Center for Child Development an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang MJ, Jiang L, Tang XJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	autism spectrum disorder subclinical epileptiform discharges levetiracetam behavioral function cognitive function randomized controlled trial Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ce84ec02bb43406184c400fc2d6b1d10
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ce84ec02bb43406184c400fc2d6b1d10
record_format	dspace
spelling	oai:doaj.org-article:ce84ec02bb43406184c400fc2d6b1d102021-12-02T01:50:07ZLevetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder1178-2021https://doaj.org/article/ce84ec02bb43406184c400fc2d6b1d102017-08-01T00:00:00Zhttps://www.dovepress.com/levetiracetam-is-associated-with-decrease-in-subclinical-epileptiform--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Minjian Wang,1–4 Li Jiang,2–5 Xiaoju Tang5 1Department of Psychology, 2Ministry of Education Key Laboratory of Child Development and Disorders, 3Key Laboratory of Pediatrics in Chongqing, 4Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, 5Department of Neurology, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China Objective: Subclinical epileptiform discharges (SEDs) are common in pediatric patients with autism spectrum disorder (ASD), but the effect of antiepileptic drugs on SEDs in ASD remains inconclusive. This physician-blinded, prospective, randomized controlled trial investigated an association between the anticonvulsant drug levetiracetam and SEDs in children with ASD. Methods: A total of 70 children with ASD (4–6 years) and SEDs identified by electroencephalogram were randomly divided into two equal groups to receive either levetiracetam and educational training (treatment group) or educational training only (control). At baseline and after 6 months treatment, the following scales were used to assess each individual’s behavioral and cognitive functions: the Chinese version of the Psychoeducational Profile – third edition (PEP-3), Childhood Autism Rating Scale (CARS), and Autism Behavior Checklist (ABC). A 24-hour electroencephalogram was recorded on admission (baseline) and at follow-up. The degree of satisfaction of each patient was also evaluated. Results: Relative to baseline, at the 6-month follow-up, the PEP-3, CARS, and ABC scores were significantly improved in both the treatment and control groups. At the 6-month follow-up, the PEP-3 scores of the treatment group were significantly higher than those of the control, whereas the CARS and ABC scores were significantly lower, and the rate of electroencephalographic normalization was significantly higher in the treatment group. Conclusion: Levetiracetam appears to be effective for controlling SEDs in pediatric patients with ASD and was also associated with improved behavioral and cognitive functions. Keywords: autism spectrum disorder, subclinical epileptiform discharges, levetiracetam, behavioral function, cognitive function, randomized controlled trialWang MJJiang LTang XJDove Medical Pressarticleautism spectrum disordersubclinical epileptiform dischargeslevetiracetambehavioral functioncognitive functionrandomized controlled trialNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 2321-2326 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	autism spectrum disorder subclinical epileptiform discharges levetiracetam behavioral function cognitive function randomized controlled trial Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	autism spectrum disorder subclinical epileptiform discharges levetiracetam behavioral function cognitive function randomized controlled trial Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Wang MJ Jiang L Tang XJ Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder
description	Minjian Wang,1–4 Li Jiang,2–5 Xiaoju Tang5 1Department of Psychology, 2Ministry of Education Key Laboratory of Child Development and Disorders, 3Key Laboratory of Pediatrics in Chongqing, 4Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, 5Department of Neurology, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China Objective: Subclinical epileptiform discharges (SEDs) are common in pediatric patients with autism spectrum disorder (ASD), but the effect of antiepileptic drugs on SEDs in ASD remains inconclusive. This physician-blinded, prospective, randomized controlled trial investigated an association between the anticonvulsant drug levetiracetam and SEDs in children with ASD. Methods: A total of 70 children with ASD (4–6 years) and SEDs identified by electroencephalogram were randomly divided into two equal groups to receive either levetiracetam and educational training (treatment group) or educational training only (control). At baseline and after 6 months treatment, the following scales were used to assess each individual’s behavioral and cognitive functions: the Chinese version of the Psychoeducational Profile – third edition (PEP-3), Childhood Autism Rating Scale (CARS), and Autism Behavior Checklist (ABC). A 24-hour electroencephalogram was recorded on admission (baseline) and at follow-up. The degree of satisfaction of each patient was also evaluated. Results: Relative to baseline, at the 6-month follow-up, the PEP-3, CARS, and ABC scores were significantly improved in both the treatment and control groups. At the 6-month follow-up, the PEP-3 scores of the treatment group were significantly higher than those of the control, whereas the CARS and ABC scores were significantly lower, and the rate of electroencephalographic normalization was significantly higher in the treatment group. Conclusion: Levetiracetam appears to be effective for controlling SEDs in pediatric patients with ASD and was also associated with improved behavioral and cognitive functions. Keywords: autism spectrum disorder, subclinical epileptiform discharges, levetiracetam, behavioral function, cognitive function, randomized controlled trial
format	article
author	Wang MJ Jiang L Tang XJ
author_facet	Wang MJ Jiang L Tang XJ
author_sort	Wang MJ
title	Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder
title_short	Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder
title_full	Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder
title_fullStr	Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder
title_full_unstemmed	Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder
title_sort	levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/ce84ec02bb43406184c400fc2d6b1d10
work_keys_str_mv	AT wangmj levetiracetamisassociatedwithdecreaseinsubclinicalepileptiformdischargesandimprovedcognitivefunctionsinpediatricpatientswithautismspectrumdisorder AT jiangl levetiracetamisassociatedwithdecreaseinsubclinicalepileptiformdischargesandimprovedcognitivefunctionsinpediatricpatientswithautismspectrumdisorder AT tangxj levetiracetamisassociatedwithdecreaseinsubclinicalepileptiformdischargesandimprovedcognitivefunctionsinpediatricpatientswithautismspectrumdisorder
_version_	1718402866560892928

Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder

Ejemplares similares